Your browser doesn't support javascript.
loading
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.
Mayer-Hamblett, Nicole; Ratjen, Felix; Russell, Renee; Donaldson, Scott H; Riekert, Kristin A; Sawicki, Gregory S; Odem-Davis, Katherine; Young, Julia K; Rosenbluth, Daniel; Taylor-Cousar, Jennifer L; Goss, Christopher H; Retsch-Bogart, George; Clancy, John Paul; Genatossio, Alan; O'Sullivan, Brian P; Berlinski, Ariel; Millard, Susan L; Omlor, Gregory; Wyatt, Colby A; Moffett, Kathryn; Nichols, David P; Gifford, Alex H.
  • Mayer-Hamblett N; Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA. Electronic address: nicole.hamblett@seattlechildrens.org.
  • Ratjen F; Translational Medicine Research Institute, The Hospital for Sick Children, Toronto, ON, Canada; Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
  • Russell R; Seattle Children's Research Institute, Seattle, WA, USA.
  • Donaldson SH; Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill, NC, USA.
  • Riekert KA; Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
  • Sawicki GS; Division of Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Odem-Davis K; Seattle Children's Research Institute, Seattle, WA, USA.
  • Young JK; Seattle Children's Research Institute, Seattle, WA, USA.
  • Rosenbluth D; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Taylor-Cousar JL; Department of Internal Medicine, National Jewish Health, Denver, CO, USA; Department of Pediatrics, National Jewish Health, Denver, CO, USA.
  • Goss CH; Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Retsch-Bogart G; Division of Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC, USA.
  • Clancy JP; Cystic Fibrosis Foundation, Bethesda, MD, USA.
  • Genatossio A; Seattle Children's Hospital, Seattle, WA, USA.
  • O'Sullivan BP; Department of Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
  • Berlinski A; Department of Pediatrics, University of Arkansas for Medical Sciences, Arkansas Children's Research Institute, Little Rock, AR, USA.
  • Millard SL; Department of Pediatrics, Spectrum Health, Helen DeVos Children's Hospital, Grand Rapids, MI, USA.
  • Omlor G; Department of Pediatrics, Akron Children's Hospital, Akron, OH, USA.
  • Wyatt CA; Department of Pediatrics, The Barbara Bush Children's Hospital, Maine Medical Center, Portland, ME, USA.
  • Moffett K; Department of Pediatrics, West Virginia University, Morgantown, WV, USA.
  • Nichols DP; Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Gifford AH; Pulmonary, Critical Care, and Sleep Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, USA; Rainbow Babies and Children's Hospital, Cleveland, OH, USA.
Lancet Respir Med ; 11(4): 329-340, 2023 04.
Article en En | MEDLINE | ID: mdl-36343646

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrosis Quística Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fibrosis Quística Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article